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Time trends on the incidence and characteristics of invasive vulvar cancer in Germany have
so far been studied in few local population- and hospital based tumor registries. We aimed
to provide an overview on recent developments of vulvar cancer in Germany, using popula-
tion-based cancer registry data.
Methods
We analyzed the data on vulvar cancer of eight population-based German cancer registries
for the period 1999-2011. ICD-10 codes and ICD-O-3 morphology codes were used to
select site and histologic types. The annual percentage change was calculated on age-
adjusted incidence rates with a joinpoint regression model.
Results
A total of 12,711 registered cases of invasive carcinoma of the vulva were included in the
analyses, hereof were 12,205 of squamous cell origin. Age-standardized incidence rates of
vulvar cancer annually increased by 6.7% (95% confidence limits: 5.6-7.9) from 1.7 per
100,000 women in 1999 to 3.6 per 100,000 women in 2011. An increase was observed
among women of all ages, and especially between 30 and 69 years of age.
Conclusion
The annual incidence of invasive carcinoma of the vulva nearly doubled in the past decade
in Germany, considerably exceeding the rates observed in other Western European
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countries. A combination of changes in risk factors, and documentation practice might have
contributed to the observed substantial increase in vulvar cancer incidence.
Introduction
Vulvar carcinoma is a rare malignancy, with an estimated age-standardized (world standard)
incidence rate up to 1.5 women per 100,000 women per year worldwide as it has also been de-
scribed for Eastern Germany in the late 1970/1980’s and early 2000’s [1,2]. An analysis based
on two western German federal population-based cancer registries estimated 2000 to 2700 new
cases per year in Germany for the time period 2000–2004 [3]. A recent report based on more
population-based cancer registries in Germany estimated around 3200 cases for the year 2010.
The incidence increases with age, the highest burden of disease is accounted for by women
over 70 years of age in Germany [4].
The most common malignant tumor of the vulva is of squamous cell origin (SCC) and can
etiologically be classified in two main subtypes: potentially associated with human papillomavi-
rus (HPV) are warty and basaloid SCC, preceded by histologically corresponding intraepithe-
lial lesions (VIN), while the non-HPV associated keratinizing SCC type is associated with
lichen sclerosus [5]. The latter is found predominantly in older women, whereas HPV related
vulvar cancer is more common in younger age [6]. Concomitant risk factors to HPV infection
are smoking and a status of immunosuppression as observed in HIV infected women and in
transplant patients [7–12].
Invasive vulvar cancer has been reported to be increasingly diagnosed in clinical settings in
Germany [13,14]. In a few other countries an increase of vulvar cancer has also been reported
[15–19]. We present the age-adjusted and age-specific incidence rates and the development of
different tumor-characteristics of invasive vulvar cancer in Germany during the past decade by
analyzing population based cancer registry data.
Methods
The database used in the present analysis was obtained from the German Centre for Cancer
Registry Data at the Robert Koch Institute (‘Zentrum für Krebsregisterdaten’, ZfKD), which
annually collects anonymized incidence and survival data from all federal states’ cancer regis-
tries. Continuous population based cancer registration is being performed since 1967 in the
federal state of Saarland, while the majority of registries in Germany started around the year
2000, and nationwide coverage was reached in 2009. Patients consent was not obtained, since
only anonymized data is available for analysis. Data are available only upon request because of
a legal restriction. Please see the Data Availability Statement for further details.
For the analyses performed in this article, we included the anonymized cancer data of pa-
tients diagnosed with invasive vulvar carcinoma (coded as C51 according to the International
Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10))
from eight population-based German cancer registries, covering approximately 60% of the
German female population for the time period of 2003–2011 in the federal states of Bavaria,
Berlin, Brandenburg, Bremen, Hamburg, Lower Saxony, Mecklenburg-W. Pomerania, Saxony,
Saxony-Anhalt, Schleswig-Holstein, the Saarland, Thuringia, and in the administrative district
of Münster. From six of the above mentioned registries, additional data for the years 1999–
2002 were available. In addition, Saarland and Hamburg contributed data from 1991 onwards.
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Cases notified by death certificate only (DCO) and cancers without further specification of
tumor morphology were studied separately.
The subsites of tumor origin were categorized into ‘Subsite specified’ (C51.0-C51.8), ‘Labiae’
(combining labiae majores et minores C51.0, C51.1), ‘Clitoris’ (C51.2), ‘Overlapping’ (C51.8),
and ‘Subsite not specified’ (C51.9).
Morphology codes were used to determine histologic subgroups according to the Interna-
tional Classification of Diseases for Oncology (ICD-O-3). Invasive malignant tumors were ex-
cluded from the main analyses if they were not further specified (morphology codes 8000–
8046), or if they were malignant melanoma (8720–8790). Groups were classified according to
‘WHO classification of tumors of the vulva’ as ‘squamous cell carcinoma (SCC)’ (8050–8084,
8090–8110) [20]; with a further differentiation into: ‘keratinizing SCC’ (8071), ‘non-keratiniz-
ing / basaloid-warty / verrucous SCC’ (8051, 8072, 8083), and ‘SCC tumors not otherwise spec-
ified’ (8070); as well as ‘epithelial tumors other than SCC and non-epithelial tumors’ (8120–
8710, 8800–9581).
Staging of disease was categorized as T1 (localized,2cm in greatest dimension), T2 (lo-
calized, >2cm in greatest dimension), and T3/T4 (regional and locally advanced, infiltrating
the urethra, vagina, anus or the surrounding tissue, mucosa of the bladder, rectum, bound to
pelvic bone), using the T-classifications of malignant tumors editions 4–6. Major changes in
the classification system of tumor stages were introduced with the 7th edition of the TNM—
classification in 2010 [21–23]. Due to missing information on the edition used in some of the
registries, the years 2010 and 2011 were excluded from the analyses on tumor stage. Sparse
data on lymph node- and distant metastasis limited further analyses according to clinical
stage groups.
Annual age-standardized (European standard) incidence rates per 100 000 women (ASIR)
were calculated for all ages combined and truncated ASIR were derived for the age groups 30
to 49 years, 50 to 69 years and 70 years and older, respectively. A standardized rate ratio and its
exact 95% confidence interval were calculated according to IARC principles and methods [24].
The average annual percentage change (AAPC) was calculated with regression models using
‘Joinpoint’, a software developed by the United States National Cancer Institute to test whether
changes in trends were statistically significantly different from zero (alpha<.05) [25].
Incidence rates of cervical adenocarcinoma (C53 with morphology codes 8140–8384) and
endometrial cancer (C54, C55) were calculated equivalently to the vulvar cancer rates. Cervical
adenocarcinoma potentially shares the same etiology with a proportion of vulva carcinomas
among younger patients, namely involvement of HPV infection; the impact of screening on in-
cidence rates, however, is smaller compared to cervical SCC. Endometrial tumors are diag-
nosed across an age distribution similar to non HPV-induced vulvar cancer. These two cancers
are usually treated within the same medical specialty (gynecology) and reported by the same
physicians. Thus they present an opportunity to examine potential systematic detection or
documentation bias.
For a comparison of German incidence data with those from other European countries, we
included DCO notified cases and cases with unspecified morphology in the German figures,
and retrieved figures on invasive vulvar cancer from selected cancer registries in Europe. As
vulvar cancer is neither depicted as a separate entity in the datasources ‘Globocan 2012’ or in
‘Cancer Incidence in Five Continents’ [6,26], cancer registries with nationwide coverage, a suf-
ficient degree of completeness, according to the International Agency for Research on Cancer
(IARC) [6], and with geographic proximity to Germany that provided vulvar cancer incidence
rates were selected: Austria, Belgium, the Czech Republic, the Netherlands, Norway, Sweden,
and the United Kingdom.
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Results
An overall number of 14,637 women with invasive vulvar cancer were observed whereof 12,711
cases (86.8%) were valid for further analyses. In total, 905 DCO cases, 607 non-DCO cases
with unspecified histology, and 414 malignant melanoma were excluded from the main analy-
sis. Median age of the included patients dropped from 73 years in 1999–2002 to 71 years in
2007–2011. Age-standardized incidence rates (ASIR) of invasive vulvar cancer annually in-
creased by 6.7% (95%CI 5.6–7.9) from 1.7 per 100,000 in 1999 to 3.7 per 100,000 in 2011, cor-
responding to a standardized rate ratio of 2.1 (95%CI 1.9–2.4). All age groups displayed this
trend (Fig 1). A decrease in the proportions of DCO notified cancers and of histologically not
further specified carcinomas was observed over time. Before exclusion of DCO notified cases,
and histologically not further specified carcinoma from the analyses, vulvar cancer annually in-
creased by 5.8% (95%CI 4.8–6.8).
Overall, 55.7% of the women were diagnosed at the age of 70 years and above, 30.8% at the
age of 50–69 years and 11.3% at the age of 30–49 years. Statistically significant annual increases
in ASIR were observed in all age groups, however most pronounced in women aged 30–49
years (AAPC +9.7%) (Table 1). The most frequently observed histological subtype was SCC
(96.0%), whereof the keratinizing type predominated in 52.4% of cases. 506 cases were of non-
epithelial origin (4.0%). A significant annual increase of SCC tumors in general was observed,
whereas the increase in the incidence rate of epithelial tumors with no SCC origin and non-
epithelial tumors remained non-significant. In 60.9% of the cases, a specific subsite was not
provided. Of all specified subsites, labial and overlapping lesions were most common, and in
15.2% percent of cases vulvar tumors were diagnosed at the clitoris. Significant annual in-
creases in the ASIR for all subsites were observable, most pronounced for clitoral tumors
(AAPC +11.7%) (Table 1). Nine out of ten women were diagnosed with a tumor staged as ‘T1’,
however, the proportion of cases with unspecified or missing information was substantial
(17.3%). We observed significant annual increases across all stages, foremost in small T1 tu-
mors (Table 1).
Fig 1. Vulvar cancer incidence rates from 1999–2011, stratified by age groups. Annual age-standardized vulvar cancer incidence rates per 100,000
women (old European Standard on a base-10 logarithmic scale), by calendar year, all ages (straight line), and for the age groups '30–49 years', '50–69
years', and '70 years plus' (dashed lines); DCO notified cases, histologically not further specified cases and melanoma excluded.
doi:10.1371/journal.pone.0128073.g001
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Additional information on age specific trends over the time periods 1999–2002, 2003–2006
and 2007–2011, as well as on cervical adenocarcinoma and endometrial carcinoma incidence is
provided in the supplement. Briefly, in patients below the age of 70 years, the increase of SCC
cases and tumors without information on subsite were significantly more pronounced. Tumors
staged as T1 and T2 significantly increased in all age groups, whereas regional and locally ad-
vanced tumors (T3/T4) significantly increased only in women below 70 years of age (S1 Table).
No changes in the annual age-standardized incidence rates of cervical adenocarcinoma and
carcinoma of the uterus were observed (S1 Fig).
Additionally, results based on data of the registries of Hamburg and Saarland indicated that
the observed increase of the incidence of invasive vulva cancers represents an ongoing develop-
ment, that had already started in the early 2000s (Fig 2).
Age-standardized incidence rates from the Netherlands and from Belgium showed an in-
crease in vulvar cancer incidence, whereas results from other European cancer registry data
suggested no change in disease burden (Table 2). In 2010/2011, the age-standardized incidence
rate in Germany was 1.2-fold to 2.2-fold higher than the rates in other European countries.
Table 1. Women’s age at diagnosis and characteristics of the invasive vulvar tumors diagnosed from
1999–2011 (for topography up to 2009).
Characteristics N AAPC of ASIRa (95%
CI)
Age at diagnosis
Overall 12711 6.7 (5.6–7.9)
30–49 years 1441 9.7 (7.6–11.9)
50–69 years 3921 8.0 (6.7–9.3)
70+ years 7084 3.8 (2.7–4.9)
Morphology
Squamous cell carcinoma (SCC) 12205 6.8 (5.8–7.9)
SCC tumors not otherwise specified 4114 8.2 (7.0–9.5)
Keratinizing SCC 6392 6.4 (5.0–7.8)
Non-keratinizing / basaloid-warty / verrucous SCC 869 6.1 (3.7–8.5)
Epithelial tumors other than SCC and non-epithelial tumors 506 3.6 ((-0.1)-7.5)
Subsite
Subsite specified 4975 6.9 (4.6–9.2)
Labiae 2742 5.3 (3.2–7.4)
Clitoris 756 11.7 (7.6–15.8)
Overlapping 1477 6.6 (3.5–9.8)
Subsite not specified 7736 6.5 (5.2–7.8)
Staging
Staging specified 8104 8.2 (7.1–9.4)
T1 3774 9.2 (7.9–10.6)
T2 3619 7.3 (5.5–9.1)
T3/T4 711 5.8 (2.4–9.2)
Staging not specified 1690 3.8 (0.6–7.2)
Staging limited to data from 1999–2009 (TNM editions 4–6).
aThe average annual percentage change (AAPC) from 1999–2011 of the age standardized (old European
standard) incidence rate (ASIR).
doi:10.1371/journal.pone.0128073.t001
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Discussion
According to data from German cancer registries, the age-standardized incidence rate of inva-
sive carcinoma of the vulva in Germany almost doubled over the past twelve years. This trend
was present in women of all age groups, however most pronounced among women aged 30–49
years and 50–69 years. As a result, the proportion of younger patients slightly increased despite
reciprocal changes in German population. Our results, using data from Eastern andWestern
German population-based cancer registries, support observations from hospital-based studies
in local Western German settings of recently increasing vulvar cancer burden in Germany [12,
13]. A rise has not been observed in a preceding population- based cancer registry study from
Eastern Germany comparing data from the years 1998–2002 with data from the years 1976–
1989 [2]. In previous studies, a moderate increase of invasive vulvar tumors across all age
groups was described for the US [27], and significant increases for Canada (especially in the
oldest age group) and the UK [18,19]. In recent Danish and Dutch registry-based studies, as
Fig 2. Vulvar cancer incidence rates in Hamburg and Saarland from 1991–2011. Annual age-standardized vulvar cancer incidence rates per 100,000
women (old European Standard) by calendar year, all ages; DCO notified cases, histologically not further specified cases and melanoma excluded.
doi:10.1371/journal.pone.0128073.g002
Table 2. Invasive vulvar cancer incidence rates from 1999–2011 in selected countries. DCO cases, melanoma, and histologically not further specified
cases included.
Countries References 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Austria Statistic Austria, Austrian national
cancer registry, personal
communication
2.0 2.0 2.1 2.0 2.1 2.2 2.1 2.2 2.1 2.3 1.8 2.2 1.9
Belgium http://www.kankerregister.org 1.7a 1.8a 1.6a 1.9a 1.9 1.9 2.1 2.1 2.1 2.2 2.3 2.6 2.2
Sweden http://www.socialstyrelsen.se/statistik/
statistikdatabas/cancer
1.8 1.8 2.0 1.5 1.7 1.7 1.8 1.9 2.1 1.8 1.5 1.9 1.8
Netherlands http://www.cijfersoverkanker.nl/home-
36.html
- - 2.2 2.1 2.4 2.3 2.4 2.4 2.8 2.7 3.1 3.0 3.4
Norway Cancer Registry of Norway, personal
communication
2.3 1.6 2.7 1.6 2.6 2.5 3.1 2.8 2.7 2.1 2.4 2.3 2.3
UK http://www.cancerresearchuk.org/
cancer-info/cancerstats/types/
2.4 2.2 2.5 2.3 2.5 2.3 2.4 2.5 2.5 2.6 2.6 2.6 2.5
Czech
Republic
http://www.svod.cz 2.9 3.0 2.2 2.6 2.6 2.7 2.9 2.6 2.4 2.5 2.5 2.7 -
Germany German cancer registries used in
this article
2.2 2.4 2.3 2.7 2.6 2.9 3.2 3.4 3.7 3.8 3.7 4.1 4.0
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well as in an Austrian retrospective study using data from 1985–1988 and 1994–1997, an in-
crease predominantly was observed in younger women [15–17]. The assessment of data from
other European cancer registries provided another source for comparison of trends in vulvar
cancer incidence rates on the general population level. Moderately rising trends over the last
decade were observed in Belgium and the Netherlands, whereas there was no evidence for in-
creasing rates in other European regions. Increasing rates described in the aforementioned
Austrian study [17] did not continue in the Austrian cancer registry data after 1999. In recent
years, the burden from vulvar cancer in Germany was considerably higher than in other
European countries.
The potential of documentation bias is a major concern in analyses of cancer registry data.
Despite of declining proportions of DCO notified cases and histologically not further speci-
fied cases, inclusion of these cases had only little effect on the annual percentage changes of
the vulvar cancer rates.—In addition, the largest increase was observed in Hamburg and Saar-
land, two federal states with a long history of cancer registration, and a high data quality [26].
Furthermore, the observed trends of the incidence rates of endometrial cancer during the
study period suggest that artifacts from changed registration might not be a major cause for
the observed findings. Theoretically, it could also be that decreasing rates of endometrial can-
cer did not become apparent due to a concurrent trend of intensified documentation or regis-
tration. We are not aware of any indication however, that selected increased registration of
gynecological tumors had occurred. An increase of the age-standardized vulvar cancer mor-
tality rates in Germany from 0.7 per 100,000 women in 1999–2002 to 0.9 per 100,000 women
in 2009–2012 [28] further supports our findings of an increase of vulvar cancer over the
last decade.
Increasing incidence rates in some cancers may also be explained by improved diagnostic
procedures, which has been observed in thyroid cancer [29], or by increased awareness of the
disease. However, the observed continuous increase in incidence rates across all T-stages sug-
gests that improved awareness and diagnosis cannot entirely explain the observed trends.
Hence, an increasing prevalence of risk factors in the population has to be considered.
About 25% of vulvar cancer worldwide is assumed to be etiologically linked to HPV infection
[30]. A more permissive sexual behavior in German female birth cohorts from 1940 onwards
[31] might have led to a higher HPV prevalence and possibly resulted in more cases of vulvar
cancer. On the other hand, incidence rates of cervical adenocarcinoma, a largely HPV related
disease, have not shown marked increases in the German registries over the same time period.
Furthermore, a genital high risk HPV prevalence of 6.3% in the German female population
aged 30 years and above is not higher than in neighboring European populations [32–34]. The
difference between German vulvar cancer incidence rates and those of other European coun-
tries remains therefore unexplained.
Smoking is considered another independent risk factor for the development of vulvar cancer
[7,8]. Concurrent to an increase in smoking prevalence in German women, the age of smoking
initiation dropped [35,36]. The strong increase in women’s tobacco consumption in Germany
in female birth cohorts 1930–1959 from about 30% to more than 60% of women ever having
smoked (health survey 2003) might have contributed to the observed increase in vulvar cancer
incidence. However, a similar increase of smoking prevalence is observed in most Western
countries, seemingly without much impact on vulva cancer rates. Lung cancer in German
women has increased by about 30% over the study period 1999–2011 [37] and one would ex-
pect the effect of smoking on vulva cancer incidence to be less pronounced than on lung can-
cer, where smoking is the predominant risk factor. Lastly, women with immunodeficiency, e.g.
due to organ transplantation or HIV infection have a substantial excess risk for vulvar cancer
[9–12]. Organ transplantation and HIV are fairly rare in Germany, but the increase in organ
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transplantation since 1997 [38], together with an increasing number of women living with HIV
[39], might have also contributed to the increase in the vulvar cancer burden in Germany.
Major strengths of our investigation are the representativeness of results for Germany, and the
large number of cases (>14,000) of this relatively rare disease, due to the large size of the female
population covered. Missing values in staging and sublocations however limit the interpreta-
tion of some of the results.
Conclusion
A doubling of incidence rates for vulvar cancer should not be ignored from an etiological per-
spective, even if vulvar cancer remains a rare disease accounting for 1.7 to 3.6 new cases per cal-
endar year in 100,000 women. A combination of risk factors (HPV, smoking, sexual behavior,
HIV, organ transplantation), and documentation practice might have contributed to the ob-
served substantial increase in vulvar cancer incidence, however there is only evidence on sub-
stantial increases in the prevalence of smoking in the German female population.
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S1 Fig. Incidence rates of cervical adenocarcinoma and cancer of the uterus from 1999–
2011. Annual age-standardized incidence rates per 100,000 women (old European Standard on
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women (old European Standard), stratified by the tumor characteristics morphology, topogra-
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